A final analysis of the Phase III TITAN study shows that Janssen’s Erleada (apalutamide), when added to androgen deprivation therapy, significantly improved overall survival in patients with metastatic castration-sensitive prostate cancer (mCSPC) compared with placebo.

Almost all people previously infected with Covid-19 have high levels of antibodies for at least six months that are likely to protect them from reinfection with the disease, results of a major UK study showed.

The chemotherapy pralatrexate and the antibiotic azithromycin were successful at preventing replication of the SARS-CoV-2 virus, according to research with Shenzhen Institutes of Advanced Technology in China.

The U.S. Food and Drug Administration approved Karyopharm Therapeutics Inc.’s Xpovio (selinexor) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

New York-based TG Therapeutics announced positive topline results from two global Phase III clinical trials, ULTIMATE I and II, of ublituximab in relapsing forms of multiple sclerosis (RMS).

AstraZeneca and Oxford University have more work to do to confirm whether their Covid-19 vaccine can be 90% effective, peer-reviewed data published in The Lancet showed, potentially slowing its eventual rollout in the fight against the pandemic.

The U.S. Food and Drug Administration requested ALX Oncology complete a standard safety study, which amounts to a partial clinical hold on a Phase II study pairing the company’s CD47 inhibitor ALX148 with Merck’s Keytruda in Head & Neck Squamous Cell Carcinoma (HNSCC).

Inovio Pharmaceuticals Inc. dosed the first participant in a mid-stage clinical trial testing the company’s Covid-19 vaccine candidate, INO-4800.

AstraZeneca Plc will likely get results of the company’s U.S. Covid-19 vaccine trial in late January 2021 and could potentially file for an emergency authorization, the chief adviser for the U.S. government’s Operation Warp Speed program said.

Johnson & Johnson launched a new late-stage trial in Britain to test a two-dose regimen of the company’s experimental Covid-19 vaccine among thousands of volunteers, as the U.S. drugmaker’s clinical studies expand by geography and type.